Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026
Blood Screening Market
The global blood screening market is projected to grow from USD 10.0 billion in 2025 to USD 18.77 billion by 2035, reflecting a compound annual growth rate (CAGR) of 6.5%. This expansion is driven by increasing demand for accurate and rapid diagnostic solutions in transfusion medicine, organ transplantation, and infectious disease screening. Key technologies underpinning this market include Nucleic Acid Testing (NAT), Elisa, Rapid Tests, Western Blot Assay, and Next-generation Sequencing (NGS), with reagents & kits, instruments, and software & services serving as critical product segments.
Blood banks and hospitals remain the primary end users, supported by advancements in automation and digital integration. The market’s growth is further catalyzed by rising healthcare expenditure, expanding screening programs, and the need for early detection of conditions such as colorectal cancer and HIV/AIDS. However, challenges such as regulatory hurdles, supply chain constraints, and ethical concerns surrounding genetic data usage may temper growth in certain regions.
Market size
Growth trajectory through 2035
Blood Screening Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Emerging opportunities added
- The blood screening market presents significant opportunities for innovation and expansion. The increasing adoption of point-of-care testing (POCT) devices offers a pathway to improve accessibility and reduce turnaround times for diagnostic results, particularly in remote or resource-limited settings. The integration of artificial intelligence (AI) and machine learning (ML) into diagnostic workflows can enhance the accuracy of test interpretation and reduce false positives, thereby improving clinical outcomes. Additionally, the growing focus on early cancer detection, such as colorectal cancer screening via fecal occult blood tests, presents a lucrative avenue for market players to develop targeted solutions. Partnerships between diagnostic manufacturers and healthcare providers, as well as collaborations with research institutions, can further accelerate the development of next-generation screening tools. Finally, the expansion of screening programs in emerging markets, driven by government initiatives and international health organizations, offers a substantial growth opportunity for vendors to establish a presence in underserved regions.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $10.00 Bn
- CAGR
- 6.50%
- Expansion
- 1.9×
Market shape
leading region
- Leading region
- North America
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ tailwind
- ▼ headwind
- Cost & supply-chain pressure
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
Capacity announcements, M&A activity, product launches, and funding rounds tracked quarterly in the full report data pack.
- Study window
- 2021–2035
- Base year
- 2025 (actuals)
Report scope
What this report answers
The specific decisions and questions covered in the 50-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Blood Screening Market today ($10.00 Bn base), and how fast will it grow at 6.5% CAGR through 2035?
- How do North America, Europe, Asia-Pacific, Latin America, and MEA compare on market share and growth rate?
- Where do Thermo Fisher Scientific, Danaher Corporation, Roche Diagnostics and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers and top restraints , with quantified CAGR impact?
- What regulatory shifts and recent tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- The blood screening market is propelled by several key factors.
- First, the rising prevalence of infectious diseases, including HIV/AIDS and hepatitis, has intensified the need for reliable and rapid diagnostic solutions, particularly in high-burden regions.
- Second, advancements in technology, such as the integration of NAT and NGS, have improved the sensitivity and specificity of screening tests, enabling earlier and more accurate detection of pathogens and genetic disorders.
- Third, government initiatives and public health policies aimed at expanding screening programs—such as newborn hearing tests and colorectal cancer screenings—have created sustained demand for diagnostic tools.
- Additionally, the growing emphasis on personalized medicine and precision diagnostics has driven the adoption of advanced technologies in clinical settings.
- Finally, the increasing healthcare expenditure in developing economies, coupled with the expansion of healthcare infrastructure, is broadening access to screening tools and fostering market growth.
Restraints
Holding it back
- Despite its growth potential, the blood screening market faces notable restraints.
- Regulatory hurdles, particularly in obtaining approvals for new technologies and assays, can delay market entry and increase compliance costs for manufacturers.
- Supply chain disruptions, such as those observed in the post-pandemic period, have also impacted the availability of critical reagents and instruments, leading to delays in production and distribution.
- Ethical and legal concerns surrounding the storage and use of genetic data, as highlighted in cases involving newborn blood samples, pose additional challenges, particularly in regions with stringent privacy laws.
- Furthermore, the high cost of advanced technologies, such as NGS and automated instruments, may limit adoption in cost-sensitive markets.
- These factors collectively constrain the market’s growth trajectory, particularly in low- and middle-income countries.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| The blood screening market is propelled by several key factors. First… | +2.9% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Despite its growth potential, the blood screening market faces notabl… | −1.2% | Global | 2025–2029 |
The blood screening market is segmented by technology, product, end user, and region. By technology, the market includes Nucleic Acid Testing (NAT), Elisa, Rapid Tests, Western Blot Assay, and Next-generation Sequencing (NGS). NAT and NGS are expected to witness the highest growth due to their superior sensitivity and ability to detect multiple pathogens simultaneously. By product, the market is divided into reagents & kits, instruments, and software & services, with reagents & kits holding the largest share due to their essential role in diagnostic workflows. By end user, blood banks and hospitals dominate the market, driven by the critical need for accurate and rapid screening in transfusion medicine and clinical diagnostics. Regionally, North America and Europe lead the market, but the Asia-Pacific region is projected to grow at the fastest pace, fueled by increasing healthcare investments and rising awareness of early disease detection.
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $10.00 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~43.1% in 2025. Driven by manufacturing scale and end-market density.
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The blood screening market is highly competitive, with a mix of global players and regional manufacturers vying for market share. The top companies, including Pfizer, Johnson & Johnson, Merck, Novartis, Roche, AbbVie, Eli Lilly, AstraZeneca, GSK, and GlaxoSmithKline, leverage their extensive R&D capabilities and global distribution networks to maintain dominance. These companies focus on strategic partnerships, mergers and acquisitions, and product innovations to strengthen their market positions. Smaller and mid-sized players often specialize in niche technologies or regional markets, offering cost-effective solutions tailored to local healthcare needs. The competitive landscape is further shaped by the increasing emphasis on automation, digital integration, and AI-driven diagnostics, which are driving consolidation and collaboration across the industry. Price competition and the need for regulatory compliance remain critical factors influencing competitive dynamics.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Thermo Fisher Scientific
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Danaher Corporation
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Roche Diagnostics
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Diagnostics
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Bio-Rad Laboratories
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
QIAGEN N.V
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Hologic Inc
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.
-
European Union
EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.
-
China / APAC
NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.
-
Global standards
ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,499
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,499
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$5,499
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
What is the worth of Blood Screening market?
Blood screening market size was valued at USD 2.44 billion in 2020 and is projected to reach USD 4.83 billion by 2029, growing at a CAGR of 7.9% from 2022 to 2029. -
What is the size of the North America Blood Screening market industry?
North America held more than 41% of the Blood Screening market revenue share in 2021 and will witness expansion in the forecast period. -
What are some of the market's driving forces?
Increased frequency of infectious diseases, increased number of blood donors, increased healthcare awareness, and increased usage of nucleic acid amplification tests are all important factors driving the global blood screening market forward (NAT). Furthermore, the market has been pushed by the government's increased healthcare initiatives, rising healthcare expenditures, and technological developments in blood screening technologies. However, market expansion is hampered by issues such as demanding regulatory approvals, a scarcity of skilled labour, and high operational expenses. -
Which are the top companies to hold the market share in Blood Screening market?
Major players such as Grifols, F. Hoffmann-La Roche, Abbott Laboratories, Biomérieux, Bio-Rad Laboratories, Inc., Siemens Healthineers, Ortho Clinical Diagnostics, Inc., Thermo Fisher Scientific, Inc., Beckman Coulter, Becton, Dickinson and Company are competing closely and dominating the market. -
What is the leading application of Blood Screening market?
The leading application of Blood Screening market in 2020 was blood banking segment. It has the biggest market share. -
Which is the largest regional market for Blood Screening market?
North America held the largest market share of Blood Screening market.
The Blood Screening Market is projected to reach $18.77 Bn by 2035, up from $10.00 Bn in 2025 — a 6.50% CAGR equating to roughly 1.9× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.